Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biovaxys Technology Corp
(CSE:
BIOV
)
0.0500
UNCHANGED
Official Closing Price
Updated: 2:06 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biovaxys Technology Corp
< Previous
1
2
Next >
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
September 23, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
September 23, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
BIOVAXYS PREPARES FOR GROUND-BREAKING STUDY ON REDUCED ACE2 BINDING CAPABILITIES OF HAPTEN-MODIFIED SARS-COV-2 PROTEINS
September 23, 2021
Via
FinancialNewsMedia
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
September 17, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D
September 17, 2021
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President’s New OSHA Mandates
September 14, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
September 14, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
FURTHER STUDY IN HUMANS SHOWS THAT THE DTH RESPONSE, THE BASIS FOR CoviDTH, IS HIGHLY DURABLE AND PERSISTS FOR AT LEAST ONE YEAR AFTER COVID-19 EXPOSURE OR VACCINE ADMINISTRATION
September 08, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums
July 22, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases
July 22, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
May 03, 2021
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
May 20, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.